382 related articles for article (PubMed ID: 33665341)
1. Disclosure of preclinical Alzheimer's disease biomarker results in research and clinical settings: Why, how, and what we still need to know.
Erickson CM; Chin NA; Johnson SC; Gleason CE; Clark LR
Alzheimers Dement (Amst); 2021; 13(1):e12150. PubMed ID: 33665341
[TBL] [Abstract][Full Text] [Related]
2. Moving beyond disclosure: Stages of care in preclinical Alzheimer's disease biomarker testing.
Ketchum FB; Chin NA; Grill J; Gleason CE; Erickson C; Clark LR; Paulsen JS; Kind AJH
Alzheimers Dement; 2022 Oct; 18(10):1969-1979. PubMed ID: 35213786
[TBL] [Abstract][Full Text] [Related]
3. Family members' perspectives on learning cognitively unimpaired older adults' amyloid-β PET scan results.
Largent EA; Abera M; Harkins K; Feldman SJ; Uhlmann WR; Roberts JS; Karlawish J;
J Am Geriatr Soc; 2021 Nov; 69(11):3203-3211. PubMed ID: 34252201
[TBL] [Abstract][Full Text] [Related]
4. Cognitively unimpaired adults' reactions to disclosure of amyloid PET scan results.
Largent EA; Harkins K; van Dyck CH; Hachey S; Sankar P; Karlawish J
PLoS One; 2020; 15(2):e0229137. PubMed ID: 32053667
[TBL] [Abstract][Full Text] [Related]
5. The Room Where It Happens: Clinician Reflections on Returning Preclinical Alzheimer's Biomarker Results to Research Participants.
Erickson CM; Chin NA; Ketchum FB; Eveler ML; Conway CE; Coughlin DM; Clark LR
J Prev Alzheimers Dis; 2024; 11(1):1-6. PubMed ID: 38230711
[TBL] [Abstract][Full Text] [Related]
6. Implications of preclinical Alzheimer's disease biomarker disclosure for US policy and society.
Erickson CM; Clark LR; Ketchum FB; Chin NA; Gleason CE; Largent EA
Alzheimers Dement (Amst); 2022; 14(1):e12339. PubMed ID: 36035626
[TBL] [Abstract][Full Text] [Related]
7. Disclosure of amyloid PET scan results: A systematic review.
Kim H; Lingler JH
Prog Mol Biol Transl Sci; 2019; 165():401-414. PubMed ID: 31481171
[TBL] [Abstract][Full Text] [Related]
8. Psychological, behavioral and social effects of disclosing Alzheimer's disease biomarkers to research participants: a systematic review.
Bemelmans SA; Tromp K; Bunnik EM; Milne RJ; Badger S; Brayne C; Schermer MH; Richard E
Alzheimers Res Ther; 2016 Nov; 8(1):46. PubMed ID: 27832826
[TBL] [Abstract][Full Text] [Related]
9. Communicating Alzheimer's biomarker results to cognitively unimpaired research participants: Satisfaction, utility, and impact on research attitudes.
Erickson CM; Ketchum FB; Basche KE; Chin NA; Eveler ML; Clark LR
Alzheimers Dement (N Y); 2024; 10(2):e12483. PubMed ID: 38882702
[TBL] [Abstract][Full Text] [Related]
10. [Evolution of the diagnostic frontiers of Alzheimer's disease and new therapeutic possibilities].
Gavrilova SI
Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(11. Vyp. 2):38-44. PubMed ID: 36412155
[TBL] [Abstract][Full Text] [Related]
11. Feasibility of virtual Alzheimer's biomarker disclosure: Findings from an observational cohort.
Erickson CM; Chin NA; Rosario HL; Peterson A; Johnson SC; Clark LR
Alzheimers Dement (N Y); 2023; 9(3):e12413. PubMed ID: 37521522
[TBL] [Abstract][Full Text] [Related]
12. On the personal utility of Alzheimer's disease-related biomarker testing in the research context.
Bunnik EM; Richard E; Milne R; Schermer MHN
J Med Ethics; 2018 Dec; 44(12):830-834. PubMed ID: 30154216
[TBL] [Abstract][Full Text] [Related]
13. Informing Disclosure: Efficacy of a Brief Educational Intervention on Research Participants' Knowledge about Alzheimer's Disease Biomarkers.
Ketchum FB; Erickson CM; Basche KE; Chin NA; Rosario HL; Johnson SC; Clark LR
J Alzheimers Dis; 2023; 96(2):515-522. PubMed ID: 37807783
[TBL] [Abstract][Full Text] [Related]
14. Disclosure of positron emission tomography amyloid imaging results: A preliminary study of safety and tolerability.
Lim YY; Maruff P; Getter C; Snyder PJ
Alzheimers Dement; 2016 Apr; 12(4):454-8. PubMed ID: 26750717
[TBL] [Abstract][Full Text] [Related]
15. Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer's disease.
Grau-Rivera O; Navalpotro-Gomez I; Sánchez-Benavides G; Suárez-Calvet M; Milà-Alomà M; Arenaza-Urquijo EM; Salvadó G; Sala-Vila A; Shekari M; González-de-Echávarri JM; Minguillón C; Niñerola-Baizán A; Perissinotti A; Simon M; Kollmorgen G; Zetterberg H; Blennow K; Gispert JD; Molinuevo JL;
Alzheimers Res Ther; 2021 Feb; 13(1):46. PubMed ID: 33597012
[TBL] [Abstract][Full Text] [Related]
16. Comprehension of an Elevated Amyloid Positron Emission Tomography Biomarker Result by Cognitively Normal Older Adults.
Mozersky J; Sankar P; Harkins K; Hachey S; Karlawish J
JAMA Neurol; 2018 Jan; 75(1):44-50. PubMed ID: 29059270
[TBL] [Abstract][Full Text] [Related]
17. The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease.
Rafii MS; Sperling RA; Donohue MC; Zhou J; Roberts C; Irizarry MC; Dhadda S; Sethuraman G; Kramer LD; Swanson CJ; Li D; Krause S; Rissman RA; Walter S; Raman R; Johnson KA; Aisen PS
Alzheimers Dement; 2023 Apr; 19(4):1227-1233. PubMed ID: 35971310
[TBL] [Abstract][Full Text] [Related]
18. Stakeholders' Views on Early Diagnosis for Alzheimer's Disease, Clinical Trial Participation and Amyloid PET Disclosure: A Focus Group Study.
Vanderschaeghe G; Vandenberghe R; Dierickx K
J Bioeth Inq; 2019 Mar; 16(1):45-59. PubMed ID: 30868358
[TBL] [Abstract][Full Text] [Related]
19. Post-disclosure distress among racial and ethnic groups in a preclinical AD trial.
Ritchie M; Salazar CR; Gillen DL; Grill JD
Alzheimers Dement; 2024 Apr; 20(4):2508-2515. PubMed ID: 38329007
[TBL] [Abstract][Full Text] [Related]
20. Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment.
Grill JD; Raman R; Ernstrom K; Sultzer DL; Burns JM; Donohue MC; Johnson KA; Aisen PS; Sperling RA; Karlawish J;
JAMA Neurol; 2020 Dec; 77(12):1504-1513. PubMed ID: 32777010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
